2月26日 - ** 制药商ArdelyxARDX.O股价盘前上涨4.4%，报5.41美元
** ARDX称 (link)，中国卫生监管机构批准了其药物tenapanor，该药有助于控制对其他疗法反应不佳的慢性肾病透析患者的磷酸盐水平。
** 批准后，ARDX的中国合作伙伴上海复星医药600196.SS将向ARDX支付500万美元。
** ARDX有资格从复星医药获得高达1亿美元的里程碑奖励和净销售额的特许权使用费
** 复星医药将以 "Wan Ti Le "品牌在中国大陆、香港和澳门销售替那帕诺。
** 该药于 2023 年获得美国 FDA 批准 (link)，商品名为 Xphozah
** 2024 年 ARDX 下跌 16.2
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.